TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18611959

Group type: EXPERIMENTAL
Intervention: 3 days of oral amoxycillin
Number of subjects: 2009

Group type: COMPARATOR
Intervention: 5 days of co-trimoxazole
Number of subjects: 2009
Study: 16481188

Group type: EXPERIMENTAL
Intervention: Intrapleural intercostal nerve block (IINB) with 20 ml (7.5 mg/ml) ropivacain injection at the dose of 4 ml for each space from the 4th to the 8th space.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-IINB (control group).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IINB group mortality and morbidity.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-IINB group mortality and morbidity.
Number of subjects: 120
Study: 14601715

Group type: EXPERIMENTAL
Intervention: Protective ventilation with low tidal volumes
Number of subjects: 0
Study: 10690696

Group type: EXPERIMENTAL
Intervention: Oral supplementation for malnourished residents (score <17)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral supplementation for residents at risk of malnutrition (score 17-23.5)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No oral supplementation for residents with score 24
Number of subjects: 88
Study: 9339691

Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg tid
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg tid
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: tolcapone groups
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study: 8274414

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy for 1 month (n = 12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Long-term oxygen therapy for 24 hours (n = 7)
Number of subjects: 19
Study: 3011048

Group type: EXPERIMENTAL
Intervention: Oral trimazosin (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous trimazosin (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active treatments (oral and intravenous trimazosin)
Number of subjects: 12
Study: 30084472

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 40
Study: 27874935

Group type: EXPERIMENTAL
Intervention: BLIS K12 (Bactoblis) daily for 6 months
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: BLIS K12 (Bactoblis) during 3 months follow-up
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (untreated) during 3 months follow-up
Number of subjects: 222
Study: 26145468

Group type: EXPERIMENTAL
Intervention: Salt treatment for 17 days along with dental sanitation and treatment of gingivitis
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 23800571

Group type: EXPERIMENTAL
Intervention: Zotarolimus eluting stents
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: Everolimus eluting stents
Number of subjects: 2265
Study: 21124768

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 894
Study: 19020153

Group type: EXPERIMENTAL
Intervention: Intranasal morphine 7.5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intranasal morphine 15 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 7.5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Oral morphine 60 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 16877482

Group type: EXPERIMENTAL
Intervention: Ciclosporin A to tacrolimus conversion (group A, target tacrolimus trough level 6-8 ng/ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ciclosporin A minimization (group B, target CsA trough level 80-100 ng/ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Graft survival in group A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Graft survival in group B
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acute rejection in group A
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Blood glucose, lipids, and blood pressure
Number of subjects: 34
Study: 12460290

Group type: EXPERIMENTAL
Intervention: Centrifuged fat
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncentrifuged fat
Number of subjects: 14
Study: 10385545

Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment after cytoreductive surgery
Number of subjects: 456
Study: 8630559

Group type: EXPERIMENTAL
Intervention: 100 mg nebulized natural-derived bovine surfactant (Alveofact)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% NaCl nebulization
Number of subjects: 12
Study: 1709311

Group type: EXPERIMENTAL
Intervention: Hemodilution with hydroxyethyl starch (10%, 200/0.5)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hemodilution group
Number of subjects: 70
Study: 7028643

Group type: EXPERIMENTAL
Intervention: High-grade purity ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slightly contaminated ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined analysis of pure vs contaminated ampicillin
Number of subjects: 0
Study: 31981584

Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quantitative feedback
Number of subjects: 0
Study: 30108162

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 28978542

Group type: EXPERIMENTAL
Intervention: Whole eggs (18 g protein, 17 g fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Egg whites (18 g protein, 0 g fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole eggs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Egg whites
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole eggs and egg whites
Number of subjects: 10
Study: 27144780

Group type: EXPERIMENTAL
Intervention: Choice, Control, and Change curriculum
Number of subjects: 1136
Study: 24258099

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 22648465

Group type: EXPERIMENTAL
Intervention: 1-set resistance training (RT) 3 times/week, 9 exercises, resistance of 3-6 repetition maximum (RM)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1-set resistance training (RT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63
Study: 19512875

Group type: EXPERIMENTAL
Intervention: LMA-ProSeal (PLMA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Endotracheal tube (control)
Number of subjects: 48
Study: 17445178

Group type: EXPERIMENTAL
Intervention: Inhibitory KIR-HLA genotype combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activating KIR genotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite inhibitory and activating KIR-HLA genotype models
Number of subjects: 0
Study: 10837378

Group type: EXPERIMENTAL
Intervention: Spectacles and occlusion (n = 69)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Spectacles only (n = 17)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Occlusion (up to >1000 hours, analyzed in blocks of 200 hours)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 86
Study: 9221313

Group type: EXPERIMENTAL
Intervention: Fatigue and neostigmine tests
Number of subjects: 11
Study: 1362592

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 117

Group type: COMPARATOR
Intervention: Antiparkinsonian drugs withdrawal
Number of subjects: 117
Study: 3890428

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) in multiple modality therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional treatment without HBO
Number of subjects: 71
Study: 30737609

Group type: EXPERIMENTAL
Intervention: HIV/STI testing acceptance
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Declined testing
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Lost to follow-up (LTFU)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Predictors of LTFU
Number of subjects: 341
Study: 29100251

Group type: EXPERIMENTAL
Intervention: 20 mg/day memantine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27770801

Group type: EXPERIMENTAL
Intervention: Balance chiropractic therapy (BCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traction therapy (TT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: TT
Number of subjects: 0
Study: 24911580

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 22424834

Group type: EXPERIMENTAL
Intervention: Combination treatment (verteporfin 6 mg/m² PDT and ranibizumab 0.5 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 255

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 255
Study: 19996947

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg/24h for 2 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18292850

Group type: EXPERIMENTAL
Intervention: ICSs alone
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: ICS plus LABA
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: General education level
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Medication compliance
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Family physicians' perception
Number of subjects: 1003

Group type: COMPARATOR
Intervention: FPs' estimate of OP symptoms
Number of subjects: 1003

Group type: COMPARATOR
Intervention: FPs' perception of treatment compliance
Number of subjects: 1003
Study: 15996628

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg, levofloxacin 500 mg and azithromycin 500 mg once-daily (ELAz)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Esomeprazole 20mg, clarithromycin 500 mg and amoxycillin 1g twice-daily (ECA)
Number of subjects: 164
Study: 14514942

Group type: EXPERIMENTAL
Intervention: Serum KL-6 levels measured by a sandwich enzyme linked immunosorbent assay
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum KL-6 levels
Number of subjects: 30
Study: 10561096

Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy (PcT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgical tracheostomy (SgT)
Number of subjects: 70
Study: 9051521

Group type: EXPERIMENTAL
Intervention: Acrylic IOLs
Number of subjects: 55

Group type: COMPARATOR
Intervention: Silicone IOLs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PMMA IOLs
Number of subjects: 55
Study: 1984762

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 315
Study: 30394552

Group type: EXPERIMENTAL
Intervention: Transfusion with one unit of RBCs at a hemoglobin level of 9.0 g/dL
Number of subjects: 58

Group type: COMPARATOR
Intervention: Transfusion with one unit of RBCs at a hemoglobin level of 7.0 g/dL
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low platelet function (assessed by MEA)
Number of subjects: 58
Study: 26577998

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination therapy (Levofloxacin + Terazosin)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All groups (Levofloxacin, Terazosin, Combination)
Number of subjects: 115
Study: 25247319

Group type: EXPERIMENTAL
Intervention: Cytological examination using a capsule sponge device
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Cytological examination combined with p53 staining
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Patient acceptability assessment using a visual analogue scale
Number of subjects: 344
Study: 22539051

Group type: EXPERIMENTAL
Intervention: Scalp cooling with 90-min post-infusion cooling time (PICT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Scalp cooling with 90-min PICT
Number of subjects: 53

Group type: COMPARATOR
Intervention: Scalp cooling with 45-min PICT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 53
Study: 20862939

Group type: EXPERIMENTAL
Intervention: Acupuncture and snake moxibustion (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Snake moxibustion (group C)
Number of subjects: 120
Study: 18666496

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multilink
Number of subjects: 18

Group type: COMPARATOR
Intervention: Die spacer group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dentin margins
Number of subjects: 18
Study: 16786786

Group type: EXPERIMENTAL
Intervention: Methods for prevention and treatment of postoperative nausea and vomiting (PONV)
Number of subjects: 0
Study: 12730560

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA; Actilyse) administered up to 6 hours after stroke
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA; Actilyse)
Number of subjects: 1000
Study: 10632905

Group type: EXPERIMENTAL
Intervention: Presurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Postsurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Number of subjects: 55
Study: 8701508

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract GB‐8 at a dose of 120 mg o.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1953853

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin after four hours of observation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravaginal 3 mg PGE2 gel followed by intravenous oxytocin four hours later
Number of subjects: 47
Study: 6602328

Group type: EXPERIMENTAL
Intervention: Aspirin 4.0 g/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diflunisal 1,000 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29596218

Group type: EXPERIMENTAL
Intervention: MCT supplementation (n = 8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No supplementation (n = 4)
Number of subjects: 12
Study: 28774521

Group type: EXPERIMENTAL
Intervention: Smart phone television display (SPTD)
Number of subjects: 38
Study: 26590513

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 70
Study: 25079399

Group type: EXPERIMENTAL
Intervention: Marginal Plaque Index (MPI)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Proximal hygiene treatment (study 1)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Toothbrushing (study 2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Turesky modification of the Quigley and Hein Index (TQHI)
Number of subjects: 131
Study: 23866471

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg) given orally at 10:00 pm the night before operation and at 7:00 am on the day of surgery
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no Trimetazidine)
Number of subjects: 170
Study: 18599252

Group type: EXPERIMENTAL
Intervention: Recursive partitioning (RP) methodology applied to drug treatment retention analysis
Number of subjects: 315
Study: 17697500

Group type: EXPERIMENTAL
Intervention: GnRH agonists (GnRHa) plus gonadotrophin therapy with corticosteroids (dexamethasone)
Number of subjects: 58

Group type: COMPARATOR
Intervention: GnRH agonists (GnRHa) plus gonadotrophin therapy with placebo
Number of subjects: 58
Study: 16138974

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (0.3 mg)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (1.0 mg)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (3.0 mg)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Subconjunctival sham injection (Control)
Number of subjects: 1186
Study: 12012289

Group type: EXPERIMENTAL
Intervention: Transient hypothyroxinemia of prematurity (THOP) defined by T4 <5.3 microg/dL without elevated TSH
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Infants with THOP
Number of subjects: 54
Study: 9449910

Group type: EXPERIMENTAL
Intervention: 0.05% tazarotene gel administered once or twice daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene gel administered once or twice daily
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 153
Study: 2699148

Group type: EXPERIMENTAL
Intervention: Postpartum insertion of intrauterine contraceptive devices (IUDs) within 10 minutes after placental delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postpartum insertion of IUDs
Number of subjects: 0
Study: 406632

Group type: EXPERIMENTAL
Intervention: Scopolamine 5 microng/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine 8 microng/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine 10 microng/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine 5 microng/kg (second experiment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine 10 microng/kg (second experiment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (second experiment)
Number of subjects: 42
Study: 31038476

Group type: EXPERIMENTAL
Intervention: Lifestyle modification treatment (diet, rehabilitation, education, behavioral therapy) for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lean individuals (controls)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prediction model based on FAT HR, resting heart rate, and FAT
Number of subjects: 200
Study: 27748623

Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI) 590 mg once daily for 84 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25648577

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: European QOL 5D Visual Analog Scale
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9
Number of subjects: 3400
Study: 23279373

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day, increased to 100 mg/day if HbA1c ≥6.5% at 16 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pioglitazone (15 mg/day, increased to 30 mg/day if HbA1c ≥6.5% at 16 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 130
Study: 18728056

Group type: EXPERIMENTAL
Intervention: Ultra-endurance exercise (cycled and jogged for 17 of 24 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control rest period
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ultra-endurance exercise
Number of subjects: 9
Study: 19786145

Group type: EXPERIMENTAL
Intervention: Polypeptide vaccine (EP-1043)
Number of subjects: 84
Study: 16924021

Group type: EXPERIMENTAL
Intervention: Acetylcholine-induced vasodilation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced vasodilation
Number of subjects: 14
Study: 15297403

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5.5 mg/ml x min day 1) and gemcitabine (1000 mg/m(2) days 1 and 8 every 21 days x 3) followed by paclitaxel (225 mg/m(2) every 21 days x 3)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m(2) day 1), vinorelbine (25 mg/m(2) days 1 and 8 every 21 days x 3) followed by docetaxel (75-100 mg/m(2) every 21 days x 3)
Number of subjects: 178
Study: 11707557

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (VLCDs) with active follow-up treatment including behavior therapy, nutritional education, and exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (VLCDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-calorie diets (400 to 800 kcal)
Number of subjects: 0
Study: 9688247

Group type: EXPERIMENTAL
Intervention: Local estrogen, physiotherapy, and electrostimulation with close follow-up
Number of subjects: 90

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 90
Study: 7867399

Group type: EXPERIMENTAL
Intervention: Selenium supplement (100 micrograms/d for 6-8 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Selenium supplement
Number of subjects: 52
Study: 2802852

Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood using hard-shell cardiotomy reservoir for up to 18 hours postoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional mediastinal drainage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood
Number of subjects: 100
Study: 1030548

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cytoxan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent chemotherapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial and crossover chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 31742630

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 474

Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (for infants born at 23 to 27 weeks' gestation)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (for infants born at 23 to 27 weeks' gestation)
Number of subjects: 474
Study: 28331925

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 46